<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39313288</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>24</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2044-6055</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>23</Day></PubDate></JournalIssue><Title>BMJ open</Title><ISOAbbreviation>BMJ Open</ISOAbbreviation></Journal><ArticleTitle>The experiences of patients with oesophageal cancer receiving chemoradiotherapy treatment: a qualitative study embedded in the SCOPE2 trial.</ArticleTitle><Pagination><StartPage>e076394</StartPage><MedlinePgn>e076394</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e076394</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjopen-2023-076394</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">This qualitative study explored patients' experiences and perceptions of the SCOPE2 trial. SCOPE2 examined radiotherapy dose escalation in patients with inoperable oesophageal cancer treated with definitive chemoradiotherapy (dCRT).</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Recruitment at five clinical sites in England and Wales, UK.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">SCOPE2 trial participants were invited to take part in interviews from across five clinical sites. Participants self-selected to take part in up to three interviews across four different time points: baseline (before treatment) and at 2-3 months, 3-6 months or 6 months+ after baseline. There were five female and five male interview participants.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">Participants were randomised to standard dose dCRT prescribed carboplatin/paclitaxel or cisplatin/capecitabine, or an escalated dose dCRT prescribed carboplatin/paclitaxel or cisplatin/capecitabine.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This qualitative study used semistructured longitudinal interviews to explore the impact of treatment on patient outlook and quality of life and the impact of the COVID-19 pandemic. Interview data were thematically analysed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">10 patients participated in 16 longitudinal interviews. Three participants were accompanied by companions. Participants experienced side-effects from radiotherapy and chemotherapy including nausea, throat pain, difficulties eating and regaining appetite, thrombosis and fatigue, although most of these symptoms gradually improved. Participants required more ongoing information and support regarding treatment side-effects and cancer status in order to improve their overall quality of life. Best practice examples involved key contacts providing practical advice and signposting support.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Participants of the SCOPE2 trial reported short and longer-term side-effects from chemoradiotherapy, but these usually lessened over time. Participants attempted to be positive about their survival prospects by readjusting their expectations, priorities and lifestyles. Providing patients with ongoing opportunities to discuss detailed and timely information regarding treatment side-effects, aftercare and cancer status could improve the overall health and well-being of patients during oesophageal cancer trials and pathways.</AbstractText><AbstractText Label="TRIAL REGISTRATION NUMBER" NlmCategory="BACKGROUND">NCT02741856; ISRCTN: 97125464.</AbstractText><CopyrightInformation>© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Holland-Hart</LastName><ForeName>Daniella</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-1127-5152</Identifier><AffiliationInfo><Affiliation>Division of Population Medicine, Cardiff University, Cardiff, UK Holland-HartD@Cardiff.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Longo</LastName><ForeName>Mirella</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-9867-3806</Identifier><AffiliationInfo><Affiliation>Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bridges</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-7665-5770</Identifier><AffiliationInfo><Affiliation>Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nixon</LastName><ForeName>Lisette Sheena</ForeName><Initials>LS</Initials><Identifier Source="ORCID">0000-0002-1270-6970</Identifier><AffiliationInfo><Affiliation>Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hawkins</LastName><ForeName>Maria</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-6669-0628</Identifier><AffiliationInfo><Affiliation>Medical Physics and Biomedical Engineering, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University College London.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crosby</LastName><ForeName>Tom</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Velindre University NHS Trust, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nelson</LastName><ForeName>Annmarie</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-6075-8425</Identifier><AffiliationInfo><Affiliation>Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT02741856</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Open</MedlineTA><NlmUniqueID>101552874</NlmUniqueID><ISSNLinking>2044-6055</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>P88XT4IS4D</RegistryNumber><NameOfSubstance UI="D017239">Paclitaxel</NameOfSubstance></Chemical><Chemical><RegistryNumber>Q20Q21Q62J</RegistryNumber><NameOfSubstance UI="D002945">Cisplatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>BG3F62OND5</RegistryNumber><NameOfSubstance UI="D016190">Carboplatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>6804DJ8Z9U</RegistryNumber><NameOfSubstance UI="D000069287">Capecitabine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004938" MajorTopicYN="Y">Esophageal Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059248" MajorTopicYN="Y">Chemoradiotherapy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036301" MajorTopicYN="Y">Qualitative Research</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017239" MajorTopicYN="Y">Paclitaxel</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002945" MajorTopicYN="N">Cisplatin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016190" MajorTopicYN="N">Carboplatin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004739" MajorTopicYN="N" Type="Geographic">England</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069287" MajorTopicYN="N">Capecitabine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014852" MajorTopicYN="N" Type="Geographic">Wales</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ONCOLOGY</Keyword><Keyword MajorTopicYN="N">Oesophageal disease</Keyword><Keyword MajorTopicYN="N">Patient-Centered Care</Keyword><Keyword MajorTopicYN="N">QUALITATIVE RESEARCH</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>18</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>4</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>20</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39313288</ArticleId><ArticleId IdType="pmc">PMC11418518</ArticleId><ArticleId IdType="doi">10.1136/bmjopen-2023-076394</ArticleId><ArticleId IdType="pii">bmjopen-2023-076394</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gavin AT, Francisci S, Foschi R, et al. Oesophageal cancer survival in Europe: a EUROCARE-4 study. Cancer Epidemiol. 2012;36:505–12. doi: 10.1016/j.canep.2012.07.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.canep.2012.07.009</ArticleId><ArticleId IdType="pubmed">22910036</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayer E, Arnold CR, Ganswindt U, et al. Memo - Magazine of European Medical Oncology. Vol. 12. Springer-Verlag Wien; 2019. Radiochemotherapy in esophageal cancer; pp. 42–5.</Citation></Reference><Reference><Citation>Allum WH, Blazeby JM, Griffin SM, et al. Guidelines for the management of oesophageal and gastric cancer. Gut. 2011;60:1449–72. doi: 10.1136/gut.2010.228254.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.2010.228254</ArticleId><ArticleId IdType="pubmed">21705456</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong RK, Malthaner R. WITHDRAWN. Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus. Cochrane Database Syst Rev. 2010;2010:CD002092. doi: 10.1002/14651858.CD002092.pub3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD002092.pub3</ArticleId><ArticleId IdType="pmc">PMC10734260</ArticleId><ArticleId IdType="pubmed">20091530</ArticleId></ArticleIdList></Reference><Reference><Citation>Pape M, Veen LM, Smit TM, et al. Late Toxicity and Health-Related Quality of Life Following Definitive Chemoradiotherapy for Esophageal Cancer: A Systematic Review and Meta-analysis. Int J Radiat Oncol Biol Phys. 2023;117:31–44. doi: 10.1016/j.ijrobp.2023.05.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijrobp.2023.05.025</ArticleId><ArticleId IdType="pubmed">37224927</ArticleId></ArticleIdList></Reference><Reference><Citation>Crosby T, Hurt CN, Falk S, et al. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. Lancet Oncol. 2013;14:627–37. doi: 10.1016/S1470-2045(13)70136-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(13)70136-0</ArticleId><ArticleId IdType="pubmed">23623280</ArticleId></ArticleIdList></Reference><Reference><Citation>Bridges S, Thomas B, Radhakrishna G, et al. SCOPE 2 – Still Answering the Unanswered Questions in Oesophageal Radiotherapy? SCOPE 2: a Randomised Phase II/III Trial to Study Radiotherapy Dose Escalation in Patients with Oesophageal Cancer Treated with Definitive Chemoradiation with an Embedded Phase II Trial for Patients with a Poor Early Response using Positron Emission Tomography/Computed Tomography. Clin Oncol. 2022;34:e269–80. doi: 10.1016/j.clon.2022.03.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clon.2022.03.019</ArticleId><ArticleId IdType="pubmed">35466013</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson A, Fenlon D, Morris J, et al. QUALZICE: a QUALitative exploration of the experiences of the participants from the ZICE clinical trial (metastatic breast cancer) receiving intravenous or oral bisphosphonates. Trials. 2013;14:325. doi: 10.1186/1745-6215-14-325.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1745-6215-14-325</ArticleId><ArticleId IdType="pmc">PMC3856513</ArticleId><ArticleId IdType="pubmed">24107437</ArticleId></ArticleIdList></Reference><Reference><Citation>Adamson D, Blazeby J, Porter C, et al. Palliative radiotherapy combined with stent insertion to reduce recurrent dysphagia in oesophageal cancer patients: the ROCS RCT. Health Technol Assess. 2021;25:1–144. doi: 10.3310/hta25310.</Citation><ArticleIdList><ArticleId IdType="doi">10.3310/hta25310</ArticleId><ArticleId IdType="pmc">PMC8182443</ArticleId><ArticleId IdType="pubmed">34042566</ArticleId></ArticleIdList></Reference><Reference><Citation>Involving people network.  [-Apr-2023]. https://involvingpeople.org/ Available. Accessed.</Citation></Reference><Reference><Citation>Hennink MM, Kaiser BN, Marconi VC. Code Saturation Versus Meaning Saturation. Qual Health Res. 2017;27:591–608. doi: 10.1177/1049732316665344.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1049732316665344</ArticleId><ArticleId IdType="pmc">PMC9359070</ArticleId><ArticleId IdType="pubmed">27670770</ArticleId></ArticleIdList></Reference><Reference><Citation>Calman L, Brunton L, Molassiotis A. Developing longitudinal qualitative designs: lessons learned and recommendations for health services research. BMC Med Res Methodol. 2013;13:14. doi: 10.1186/1471-2288-13-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2288-13-14</ArticleId><ArticleId IdType="pmc">PMC3598728</ArticleId><ArticleId IdType="pubmed">23388075</ArticleId></ArticleIdList></Reference><Reference><Citation>Braun V, Clarke V. APA Handbook of Research Methods in Psychology, Vol 2: Research Designs: Quantitative, Qualitative, Neuropsychological, and Biological. Washington: American Psychological Association; 2012. Thematic analysis; pp. 57–71.</Citation></Reference><Reference><Citation>Sibeoni J, Picard C, Orri M, et al. Patients’ quality of life during active cancer treatment: a qualitative study. BMC Cancer. 2018;18:951. doi: 10.1186/s12885-018-4868-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12885-018-4868-6</ArticleId><ArticleId IdType="pmc">PMC6172766</ArticleId><ArticleId IdType="pubmed">30286733</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham L, Wikman A. Toward improved survivorship: supportive care needs of esophageal cancer patients, a literature review. Dis Esophagus. 2016;29:1081–9. doi: 10.1111/dote.12424.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dote.12424</ArticleId><ArticleId IdType="pubmed">26455727</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsen MK, Schultz H, Mortensen MB, et al. Patients’ Experiences With Illness, Treatment, and Decision-Making for Esophageal Cancer: A Qualitative Study in a Danish Hospital Setting. Glob Qual Nurs Res. 2020;7:2333393620935098. doi: 10.1177/2333393620935098.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2333393620935098</ArticleId><ArticleId IdType="pmc">PMC7328478</ArticleId><ArticleId IdType="pubmed">32656299</ArticleId></ArticleIdList></Reference><Reference><Citation>Malmström M, Klefsgård R, Johansson J, et al. Patients’ experiences of supportive care from a long-term perspective after oesophageal cancer surgery - a focus group study. Eur J Oncol Nurs. 2013;17:856–62. doi: 10.1016/j.ejon.2013.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejon.2013.05.003</ArticleId><ArticleId IdType="pubmed">23732012</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou B, Tu Y, Liao D, et al. Radical esophagectomy for stage II and III thoracic esophageal squamous cell carcinoma followed by adjuvant radiotherapy with or without chemotherapy: Which is more beneficial? Thorac Cancer. 2020;11:631–9. doi: 10.1111/1759-7714.13307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1759-7714.13307</ArticleId><ArticleId IdType="pmc">PMC7049519</ArticleId><ArticleId IdType="pubmed">31943824</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukherjee S, Hurt CN, Adams R, et al. Efficacy of early PET-CT directed switch to carboplatin and paclitaxel based definitive chemoradiotherapy in patients with oesophageal cancer who have a poor early response to induction cisplatin and capecitabine in the UK: a multi-centre randomised controlled phase II trial. eClinMed. 2023;61:102059. doi: 10.1016/j.eclinm.2023.102059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2023.102059</ArticleId><ArticleId IdType="pmc">PMC10318451</ArticleId><ArticleId IdType="pubmed">37409323</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke C, McCorry NK, Dempster M. The role of identity in adjustment among survivors of oesophageal cancer. J Health Psychol. 2011;16:99–108. doi: 10.1177/1359105310368448.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1359105310368448</ArticleId><ArticleId IdType="pubmed">20929944</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts D, Calman L, Large P, et al. A revised model for coping with advanced cancer. Mapping concepts from a longitudinal qualitative study of patients and carers coping with advanced cancer onto Folkman and Greer’s theoretical model of appraisal and coping. Psychooncology. 2018;27:229–35. doi: 10.1002/pon.4497.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pon.4497</ArticleId><ArticleId IdType="pubmed">28695612</ArticleId></ArticleIdList></Reference><Reference><Citation>O’Brien CW, Moorey S. Outlook and adaptation in advanced cancer: a systematic review. Psychooncology. 2010;19:1239–49. doi: 10.1002/pon.1704.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pon.1704</ArticleId><ArticleId IdType="pubmed">20200856</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker R, Szanton SL, Wenzel J. Working Toward Normalcy Post-Treatment: A Qualitative Study of Older Adult Breast and Prostate Cancer Survivors. Oncol Nurs Forum. 2015;42:E358–67. doi: 10.1188/15.ONF.E358-E367.</Citation><ArticleIdList><ArticleId IdType="doi">10.1188/15.ONF.E358-E367</ArticleId><ArticleId IdType="pmc">PMC4750471</ArticleId><ArticleId IdType="pubmed">26488842</ArticleId></ArticleIdList></Reference><Reference><Citation>Molassiotis A, Rogers M. Symptom experience and regaining normality in the first year following a diagnosis of head and neck cancer: a qualitative longitudinal study. Palliat Support Care. 2012;10:197–204. doi: 10.1017/S147895151200020X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S147895151200020X</ArticleId><ArticleId IdType="pubmed">22613011</ArticleId></ArticleIdList></Reference><Reference><Citation>Henselmans I, Jacobs M, van Berge Henegouwen MI, et al. Postoperative information needs and communication barriers of esophageal cancer patients. Patient Educ Couns. 2012;88:138–46. doi: 10.1016/j.pec.2011.12.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pec.2011.12.004</ArticleId><ArticleId IdType="pubmed">22244819</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh J, Young JM, Harrison JD, et al. What is important in cancer care coordination? A qualitative investigation. Eur J Cancer Care (Engl) 2011;20:220–7. doi: 10.1111/j.1365-2354.2010.01187.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2354.2010.01187.x</ArticleId><ArticleId IdType="pubmed">20477854</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen M, Yagil D, Aviv A, et al. Cancer patients attending treatment during COVID-19: intolerance of uncertainty and psychological distress. J Cancer Surviv. 2022;16:1478–88. doi: 10.1007/s11764-021-01126-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11764-021-01126-3</ArticleId><ArticleId IdType="pmc">PMC8783796</ArticleId><ArticleId IdType="pubmed">35066775</ArticleId></ArticleIdList></Reference><Reference><Citation>Miaskowski C, Paul SM, Snowberg K, et al. Loneliness and symptom burden in oncology patients during the COVID-19 pandemic. Cancer. 2021;127:3246–53. doi: 10.1002/cncr.33603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.33603</ArticleId><ArticleId IdType="pmc">PMC9508796</ArticleId><ArticleId IdType="pubmed">33905528</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Busaidi ZQ. Qualitative research and its uses in health care. Sultan Qaboos Univ Med J. 2008;8:11–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3087733</ArticleId><ArticleId IdType="pubmed">21654952</ArticleId></ArticleIdList></Reference><Reference><Citation>Lv Y, Zhang J, Qiao L. Quality of life in patients with esophageal cancer receiving definitive chemoradiotherapy or esophagectomy. Mol Clin Oncol. 2014;2:870–4. doi: 10.3892/mco.2014.313.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mco.2014.313</ArticleId><ArticleId IdType="pmc">PMC4106730</ArticleId><ArticleId IdType="pubmed">25054060</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermus M, van der Wilk BJ, Chang RTH, et al. Patient preferences for active surveillance vs standard surgery after neoadjuvant chemoradiotherapy in oesophageal cancer treatment: The NOSANO-study. Int J Cancer. 2023;152:1183–90. doi: 10.1002/ijc.34327.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.34327</ArticleId><ArticleId IdType="pmc">PMC10092042</ArticleId><ArticleId IdType="pubmed">36250325</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>